ADMETRx, a contract research group, has collaborated with Roche to advance the development of ADMETRx proprietary multi-criteria decision-making models applied to drug discovery.    ADMETRx and Roche both recognize how comprehensive data integration may offer significant advantages to discovery groups in selecting candidates for advancement. Phil Burton, CEO and chief scientific officer of ADMETRx, said: "Effectively using all the data available in a discovery program to prioritize or advance candidates with the best development potential is a significant challenge in the pharmaceutical industry. The multi-criteria decision-making methods developed by ADMETRx are intended to help Roche scientists to make these critical decisions, ultimately improving the success of candidates at each step in the development process."